Shares of ASLAN PHARMACEU/ADR (NASDAQ:ASLN) have earned a consensus broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and two have given a strong buy rating to the company.
Brokers have set a 1-year consensus price target of $4.67 for the company and are forecasting that the company will post ($0.16) earnings per share for the current quarter, according to Zacks. Zacks has also given ASLAN PHARMACEU/ADR an industry rank of 59 out of 255 based on the ratings given to its competitors.
Several equities research analysts have recently weighed in on ASLN shares. Piper Jaffray Companies raised ASLAN PHARMACEU/ADR from a “neutral” rating to an “overweight” rating and set a $8.00 target price for the company in a research report on Monday. BTIG Research downgraded ASLAN PHARMACEU/ADR from a “buy” rating to a “neutral” rating in a report on Monday, November 11th. HC Wainwright reissued a “buy” rating and set a $2.00 price target on shares of ASLAN PHARMACEU/ADR in a research report on Monday, November 25th. Finally, Zacks Investment Research upgraded ASLAN PHARMACEU/ADR from a “hold” rating to a “strong-buy” rating and set a $2.00 price target for the company in a report on Monday, November 4th.
ASLAN PHARMACEU/ADR (NASDAQ:ASLN) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.19. As a group, equities research analysts anticipate that ASLAN PHARMACEU/ADR will post -0.69 EPS for the current fiscal year.
An institutional investor recently raised its position in ASLAN PHARMACEU/ADR stock. FNY Investment Advisers LLC increased its holdings in ASLAN PHARMACEU/ADR (NASDAQ:ASLN) by 57.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 19,100 shares of the company’s stock after acquiring an additional 6,993 shares during the quarter. FNY Investment Advisers LLC owned approximately 0.06% of ASLAN PHARMACEU/ADR worth $33,000 as of its most recent filing with the SEC. Institutional investors own 7.12% of the company’s stock.
About ASLAN PHARMACEU/ADR
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.